Verenium Corporation Reports Financial Results For the First Quarter Ended March 31, 2013

Published: May 10, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, May 10, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported operating highlights and financial results for the first quarter ended March 31, 2012.

"The first quarter was a turning point for Verenium. Beyond the repayment of our outstanding debt, we also initiated discussions with a wide array of companies who recognize the value of our technology, and signed agreements with both Tate & Lyle and DSM that validate our unique capabilities," said James Levine, President and Chief Executive Officer at Verenium.

Help employers find you! Check out all the jobs and post your resume.

Back to news